Astrazeneca: two anti-cancer drug approvals in Japan
(CercleFinance.com) - AstraZeneca and Merck announce that the Japanese health authorities have approved their tablet Lynparza (olaparib) for patients with metastatic breast cancer who have previously received chemotherapy.
This endorsement - the second for the product in Japan after that of ovarian cancer - is based on data from the OlympiAD Phase III trial, which demonstrated a significantly longer progression-free survival of the disease.
In addition, AstraZeneca reports that its Imfinzi (durvalumab) has been approved in Japan for maintenance treatment in locally advanced non-resectable non-small cell lung cancer (NSCLC), based on the PACIFIC Phase III trial.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
This endorsement - the second for the product in Japan after that of ovarian cancer - is based on data from the OlympiAD Phase III trial, which demonstrated a significantly longer progression-free survival of the disease.
In addition, AstraZeneca reports that its Imfinzi (durvalumab) has been approved in Japan for maintenance treatment in locally advanced non-resectable non-small cell lung cancer (NSCLC), based on the PACIFIC Phase III trial.
Copyright (c) 2018 CercleFinance.com. All rights reserved.